Τόμος 12 (1998) – Τεύχος 1 & 2 – Άρθρο 1 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 12 (1998) – Issue 1 & 2 – Article 1 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

1. 2^nd Cardiology Department and 2. Laboratory of Pharmacology, Faculty of Medicine, Aristotle University of Thessaloniki, Greece

Accepted for publication: 20 September 1997

pharmakonpress[at]pharmakonpress[.]gr

2.      Atlas S.A., Laragh J.H.: Atrial natriuretic factor and its in-volvement in hypertensive disorders. )n: (Laragh J.H., Brenner B.M., eds) Hypertension, pp. 861-833, Raven Press, New York, 1990

3.      Witdey G.M., Misono K.S., Graham R.M.: Atrial natriuretic factor: Biosynthesis and mechanism of action. In: (Fozzard H.A., et al, eds) The Heart and Cardiovascular System. 2nd Ed., pp. 1977-1796, Raven Press, New York, 1992

A. Day M.L., Schwartz D., Wiegand R.C., et al.: Ventricular atriopeptin. Hypertension 9: 485-491 (1987)

5.      Lang R.E., Tholken H., Ganten D., et al.: Atrial natriuretic factor: a circulating hormone stimulated by volume loading factor. Nature 314: 264-266 (1985)

6.      Kohno M., Clegg K.B., Sambhi M.P.: Effects of volume change on circulating immunoreactive atrial natriuretic factor in rat. Hypertension 10: 171-175 (1987)

7.       Ogawa Y., Nakao Κ.: Brain natriuretic peptide as a cardiac hormone in cardiovascular disorders. In: (Laragh J.H., Brenner B.M., eds) Hypertension, 2nd, pp. 833-840, Raven Press, New York, 1995

8.      Lewicki J., Protter A.: Physiological studies of natriuretic peptide family. In: (Laragh J.H., Brenner B.M., eds) Hyper-tension, 2nd, pp. 1029-1048, Raven Press, New York, 1995

9.      Gunning M., Brenner B.: Urodilantin In: (Laragh J.H., Brenner B.M., eds) Hypertension, 2nd, pp. 833-840, Raven Press, New York, 1995

10.    Waldman S., Rapaport R.M., Murad F.: Atrial natriuretic factor activates particulate guanylate cyclase and elevates cyclic GMP in rat tissues. J. Biol. Chem. 254: 14332-14334 (1984)

11.     Racz K., Kuckel O., Buu N.T., et al.: Atrial natriuretic factor, catecholamines, and natriuresis. N. Engl. J. Med. 314: 312-323 (1986)

12.    Huang C.L., Lewiski J., Johnson L.K., Cogan M.G.: Renal mechanisms of action of rat atrial natriuretic factor. J. Clin. Invest. 75: 769-773 (1985)

13.    Fried T.A., McCoy R.N., Osgood R.W., et al.: Effect of atriopeptin II on determinants of glomerular filtration rate in the in vitro perfused dog glomerulus. Am. J. Physiol. 250: F1119-F1122 (1986)

14.    Sagnella G.A., Mardanda N.M., Shore A.C., MacGragor G.A.: Effects of changes in dietary sodium intake and saline infusion on immunoreactive atrial natriuretic peptide in human plasma. Lancet II: 1208-1210 (1985)

15.    Raine A.E.G., Erne P., Burgisser E., et al.: Atrial natriuretic factor and atrial pressure in patients with congestive heart failure. N. Engl. J. Med. 315: 533-537 (1986)

16.    Sagawara A., Nakao K., Sakamoto M., et al.: Plasma concentration of atrial natriuretic polypeptide in essential hypertension. Lancet II: 1426-1427 (1985)

17.     Sagnella G.A., Markanda N.D., Shore A.C., MacGregor G.A.: Raised circulating levels of atrial natriuretic peptides in essential hypertension. Lancet 1: 179-181 (1986)

18.    Montorsi P., Tonolo G., Polonia J., et al.: Correlates of plasma atrial natriuretic factor in health and hypertension. Hypertension 10: 570-576 (1987)

19.    Sarzani R., Paci V.M., Wingaretti C.M., et al.: Fasting inhibits natriuretic peptides clearance receptor expression in rat adipose tissue. J. Hypert. 13: 1241-1246 (1955)

20 Papadopoulos C., Kokkas V., Kotridis P., Kyriakou P. et al.: The effect of prolonged administration of β1-blocker bisoprolol on arterial pressure and atrial natriuretic peptide in arterial hypertension. 3^rd Panhellenic Congr. Arter. Hypert., Book of Abstracts, Abs: 31 (Gr), 1991

21.    Papadopoulos C., Kokkas V., Kotridis P., et al.: The effects of prolonged administration of the β₁-blocker bisoprolol on arterial pressure and atrial natriuretic peptide in arterial hypertension. Arter. Hypert. (Gr) 1: 201-205 (1992)

22.    Papadopoulos C.L., Kokkas B.A., Kotridis P.S., Gitsios C.Th., Sakadamis G.C., Kanonidis J.E., Kotoula M.I., Paradelis A.G.: The Effect of ß1-Blocker Bisoprolol on Atrial Natriuretic Peptide Plasma Levels in Hypertensive Patients. Intern. J. Angiol. 4: 165-168 (1995)

23.    Papadopoulos C., Kokkas B., Kotridis P., Gitsios C., Sakadamis G., Kanonidis J, Faitatziades D., Pilis A., Theodoridis E., Paradelis A.: Plasma Atrial Natriuretic Peptide in Essential Hypertension after Angiotensin Converting Enzyme Inhibition. Intern. J. Angiol. 4: 44-45 (1995)

24.    Matsubara H., Hirata Y., Yoshimi H., et al.: Role of calcium and protein kinase C in ANP secretion be cultured rat cardiocytes. Am. J. Physiol.: H405-H409 (1988)

25.    Shields P.P., Glembotski C.C.: Regulation of atrial natriuretic factor-secretion from neonatal rat primary atrial cultures by activators of protein kinases A and C. J. Biol. Chem. 264: 9322-9328 (1989)

26.    Hollenbeck M., Plum J., Hearing P., et al.: Influence of betaxolol on renal function and atrial natriuretic peptide in essential hypertension. J. Hypertension. 9: 819-824 (1991)

27.    Hama J., Nagata S ., Takenaka T., Kino H., Shimada S., Horiuchi M., Katori R.: Atrial natriuretic peptide and antihypertensive action due to beta-blockade in essential hypertensive patients. Angiology 46: 511-516 (1995)

28.    Papadopoulos C., Kokkas B., Kotridis P., Kanonidis J., Karamouzis M.: The effect of β₁-blocker/β₂-agonist celiprolol on Atrial natriuretic plasma levels in hypertensive patients. Unpublished yet data

29.    Sonotani N., Kubo S., Nishioka A. et al.: Electrocardiographic and echocardiographic changes after one to two-years treatment of hypertension. Jpn Heart J. 22: 325-333 (1981)

30.    Geller D., Currie M., Wakitani K., et al.: Atriopeptines. Bioch. Biophys. Res. Com. 120: 333-338 (1984)

31.    Guyton A.C., Gall J.E., Coleman T.G., Manning R.D.; The dominant role of the kidneys in the long-term regulation of arterial pressure in normal and hypertensive states. In: (Laragh J.H., Brenner B.M., eds) Hypertension, pp. 1029-1052, Raven Press, New York, 1990

32.    London G.M., Levenson J.A., London A.M.: Renal and systolic hemodynamics in sustained essential hypertension. Hypertension 6: 743-754 (1984)

33.    Path M., Steimer C., Cazor J.L., Schwartz J.: Study of the dose response of betaxolol in arterial hypertension. Therapie 38: 143-148 (1983)

34.    Hanssen W.M.T., DeZeeuw D., Van der Hem G., De Jong P.E.: Antihypertensive effect of a 5 day infusion of atrial natriuretic factor in humans. Hypertension 13: 640-646 (1989)

35.    Struyker-Boudier H.A.J., Smits Antihypertensive action of beta-adrenoreceptor blocking drugs. Am. J. Hypertens. 2: 237S-240S (1989)

36.    Epstein M., Oster J.R.: Beta-blockers and the kidney. Miner. Electrolyte Metab. 8: 237-254 (1982)

37.    Sonnenberg H., Veress A.T.: Cellular mechanism of release of atrial natriuretic factor. Biochem. Biophys. Res. Commun. 124: 443-449 (1984)

38.    Gavras I., Gavras H.: Does bradykinin contribute to the actions of angiotensin converting enzyme inhibitors? ACE Report 95: 1-7 (1993)

39.    Garrisson J., Peach M.: Renin and angiotensin. In: (Hardman J. et al., eds) Goodman and Gilman’s. The Pharmacological Basis of Therapeutics. Pp. 733-758, Pergamon Press, New York, 1996

40.    Zusman R.: Effects of converting enzyme inhibitors on the renin-angiotensin aldosterone, bradykinin and arachidonic acid-prostaglandin systems. Correlation of chemical structures and biological activity. Am. Kidney Dis. 10 (suppl.1): 13- 23 (1967)

41.    Gros C., Noel N, Souque A., Schwartz J., Danvy D.: Mixed inhibitors of angiotensin coverting enzymes (EC 3,4,15,1) and enkephalines (EC 3,4,24,11): Rational design, properties and potential cardiovascular applications of glycopril and alatriopril. Proc. Nat. Acad. Sci. USA 88: 4212-4214 (1988)

42.    Hooper N., Hryszko J., Oppong S., Turner A.: Inhibition by converting enzyme inhibitors of pig kidney aminopeptidase P. Hypertension 19: 281-285 (1995)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr